Altimmune (ALT) Tax Provisions (2012 - 2025)

Altimmune (ALT) posted quarterly Tax Provisions of -$18.0 million for Q4 2025, down 2538.03% quarter-over-quarter from -$681000.0 in Q1 2025.

Altimmune (ALT) Tax Provisions (2012 - 2025) Analysis & Trends

Altimmune (ALT) has reported Tax Provisions for 11 consecutive years, with -$18.0 million the latest figure, recorded in Q4 2025.

In Q4 2025, Tax Provisions changed N/A year-over-year to -$18.0 million; the TTM figure through Dec 2025 stood at -$18.6 million (changed N/A YoY), while the FY2025 annual figure was -$18.6 million, up 6.59% from the prior year.
Tax Provisions eased to -$18.0 million in Q4 2025 per ALT's latest filing, from -$681000.0 in the prior quarter.
Across five years, Tax Provisions topped out at $144000.0 in Q4 2022 and bottomed at -$18.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	59.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	75.45 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	267.73
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.31 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.90 Mn
10	Altimmune	571.75 Mn	571.75 Mn	-	-

Download Data